Drug Sales Reveal Our Lifestyle Woes

Drug Sales Reveal Our Lifestyle Woes

NEW DELHI, 22 OCT 2019:


Anti-infectives along with medicines for cardiac diseases, diabetes, gastro-intestinal and respiratory problems garnered the highest sales in the Indian pharmaceutical market in last one year, pointing to a rapidly growing burden of lifestyle-related ailments.


Indians spent over Rs 1,36,000 crore on medicines in last one year ending September 2019, of which 31% was spent on medicines for diabetes, heart disorders and other chronic ailments.


This is also the fastest growing segment at 13% as compared to acute therapies which accounted for 47% of the market but grew by 11.7% and sub-chronic segment at 10.7%, according to data released by All India Organisation of Chemists & Druggists (AIOCD).


While anti-infectives topped the list of medicines with highest sales value, those for cardiac problems, diabetes and gastro-intestinal disorders were among the top five, with only cardiac and anti-diabetes drugs registering double digit growth of 12.6% and 14.9%, respectively, for the year. The overall drug sales grew by 9.8% during the period.


People spent over Rs 17,000 crore on cardiac drugs, around Rs 15,400 crore for gastro-intestinal disorders and over Rs 13,360 crore on anti-diabetes medicines in the last 12 months. Anti-infectives accounted for the highest sales of over Rs 18,413 crore.


“Sales of anti-diabetic drugs has increased due to multiple factors like increased number of patients, more frequent diagnosis, increasing use of more expensive drugs and insulin. Importantly, use of conventional low cost drugs/insulin could help manage about 60-70% cases of diabetes in India, thus reducing out of pocket cost for patients,” says Dr Anoop Misra, Chairman Fortis C-Doc.


Maximum drug launches were in cardiovascular and respiratory segments. Around 78 new drugs were launched in September alone. Of these, 18 were to treat cardiovascular diseases, 17 were vitamins, minerals and nutrients and 14 were in in the respiratory segment.


Not just in terms of value but volume growth have also gained momentum, a senior industry executive said.


“Increasing disease burden, growing awareness, availability and affordability of treatment along with enhanced insurance penetration have all resulted in higher sales of medicines. Besides, there is no doubt that the NCD (non-communicable disease) segment is growing rapidly leading to higher growth in segments like cardiac and diabetes,” he said. The data also show the top ten corporates gradually increasing there market share in the chronic segment. ET Healthworld